As of 2024-12-13, the EV/EBITDA ratio of Coherus BioSciences Inc (CHRS) is -2.93. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CHRS's latest enterprise value is 339.63 mil USD. CHRS's TTM EBITDA according to its financial statements is -116.10 mil USD. Dividing these 2 quantities gives us the above CHRS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.6x - 16.2x | 11.4x |
| Forward P/E multiples | 11.1x - 23.8x | 16.4x |
| Fair Price | (12.65) - (17.77) | (15.51) |
| Upside | -943.6% - -1284.9% | -1133.7% |
| Date | EV/EBITDA |
| 2024-12-10 | -3.03 |
| 2024-12-09 | -3.12 |
| 2024-12-06 | -3.12 |
| 2024-12-05 | -2.94 |
| 2024-12-04 | -3.13 |
| 2024-12-03 | -3.13 |
| 2024-12-02 | -2.80 |
| 2024-11-29 | -2.65 |
| 2024-11-27 | -2.69 |
| 2024-11-26 | -2.71 |
| 2024-11-25 | -2.64 |
| 2024-11-22 | -2.52 |
| 2024-11-21 | -2.53 |
| 2024-11-20 | -2.53 |
| 2024-11-19 | -2.25 |
| 2024-11-18 | -2.21 |
| 2024-11-15 | -2.18 |
| 2024-11-14 | -2.20 |
| 2024-11-13 | -2.21 |
| 2024-11-12 | -2.25 |
| 2024-11-11 | -2.21 |
| 2024-11-08 | -2.25 |
| 2024-11-07 | -2.25 |
| 2024-11-06 | -2.16 |
| 2024-11-05 | -2.16 |
| 2024-11-04 | -2.10 |
| 2024-11-01 | -2.15 |
| 2024-10-31 | -2.18 |
| 2024-10-30 | -2.18 |
| 2024-10-29 | -2.17 |
| 2024-10-28 | -2.15 |
| 2024-10-25 | -2.21 |
| 2024-10-24 | -2.22 |
| 2024-10-23 | -2.24 |
| 2024-10-22 | -2.29 |
| 2024-10-21 | -2.31 |
| 2024-10-18 | -2.31 |
| 2024-10-17 | -2.28 |
| 2024-10-16 | -2.32 |
| 2024-10-15 | -2.34 |
| 2024-10-14 | -2.37 |
| 2024-10-11 | -2.42 |
| 2024-10-10 | -2.40 |
| 2024-10-09 | -2.43 |
| 2024-10-08 | -2.47 |
| 2024-10-07 | -2.50 |
| 2024-10-04 | -2.47 |
| 2024-10-03 | -2.47 |
| 2024-10-02 | -2.45 |
| 2024-10-01 | -2.45 |